ustekinumab

Home
Ligands
ustekinumab

GtoPdb Ligand ID: 6885

Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20

ustekinumab is an approved drug (FDA (2009), EMA (2009))

Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:

Name	Trade name	Company	Clinical Phase	Indications
ustekinumab-auub; ABP 654	Wezlana	Amgen	Approved (2023 FDA)	As per reference agent; Interchangeable with reference agent

References
1. Giles-Komar J, Knight DM, Peritt D, Scallon B, Shealy D. (2005) Also an IL-12 anti-idiotype antibody to the antibody. Patent number: US6902734. Assignee: Centocor, Inc.. Priority date: 07/08/2000. Publication date: 07/06/2005.
2. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G et al.. (2019) Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 381 (13): 1201-1214. [PMID:31553833]

References

1. Giles-Komar J, Knight DM, Peritt D, Scallon B, Shealy D. (2005)
Also an IL-12 anti-idiotype antibody to the antibody.
Patent number: US6902734. Assignee: Centocor, Inc.. Priority date: 07/08/2000. Publication date: 07/06/2005.

2. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G et al.. (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med, 381 (13): 1201-1214. [PMID:31553833]